We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed Circ. Rejects Amgen Bid For DNA Patent

Law360 (April 3, 2009, 12:00 AM EDT) -- In a decision that raises the bar for biotechnology companies to protect their work on DNA sequencing, Amgen Inc. has lost a federal appeals court fight to obtain a patent related to so-called natural killer cells in bone marrow.

In a widely watched case, the U.S. Court of Appeals for the Federal Circuit on Friday upheld the U.S. Patent and Trademark Office's rejection of the application by two Amgen scientists — Marek Z. Kubin and Raymond G. Goodwin — for a patent related to sequencing a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.